Apollomics has dosed the first patient in a China Phase III trial of uproleselan to treat relapsed or refractory acute myeloid leukemia (AML). APL-106 is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with blood cancer cells, disrupting leukemic cell resistance within the bone marrow microenvironment. In 2020, Apollomics in-licensed Greater China rights to uproleselan from GlycoMimetics in a two-drug, $189 million deal. Apollomics is headquartered in Foster City , CA with China operations in Hangzhou and Shanghai . More details.... Share this with colleagues: // //